On October 2, 2018, Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, announced the closing of its underwritten public offering of 4,600,000 American Depositary Shares (“ADSs”) representing 4,600,000 ordinary shares, at a public offering price of $18.00 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 ADSs. The aggregate gross proceeds to Nightstar from the offering were $82.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Nightstar. All ADSs sold in the offering were offered by Nightstar.

Brian Johnson led the WilmerHale team in the representation of Nightstar in this offering, which included Richard Andersen, Avery Reaves, Ryan Crane and Heidi Treiber.

The press release announcing the closing of this transaction can be found at www.nightstartx.com.